These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28494683)

  • 1. What is clearance worth? Patients' stated risk tolerance for psoriasis treatments.
    Fairchild AO; Reed SD; Johnson FR; Anglin G; Wolka AM; Noel RA
    J Dermatolog Treat; 2017 Dec; 28(8):709-715. PubMed ID: 28494683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K.: results from a discrete-choice experiment.
    Gonzalez JM; Johnson FR; McAteer H; Posner J; Mughal F
    Br J Dermatol; 2017 Mar; 176(3):777-785. PubMed ID: 27292093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy.
    Kauf TL; Yang JC; Kimball AB; Sundaram M; Bao Y; Okun M; Mulani P; Hauber AB; Johnson FR
    J Dermatolog Treat; 2015; 26(6):507-13. PubMed ID: 25946139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis.
    Seston EM; Ashcroft DM; Griffiths CE
    Arch Dermatol; 2007 Sep; 143(9):1175-9. PubMed ID: 17875880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating Risk Tolerance from a Systematic Review of Preferences: The Case of Patients with Psoriasis.
    Gonzalez JM
    Patient; 2018 Jun; 11(3):285-300. PubMed ID: 29332301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
    Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists.
    Ashcroft DM; Seston E; Griffiths CE
    Br J Dermatol; 2006 Dec; 155(6):1236-41. PubMed ID: 17107395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients' and Physicians' Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare).
    Schaarschmidt ML; Herr R; Gutknecht M; Wroblewska K; Gerdes S; Sticherling M; Augustin M; Peitsch WK
    Acta Derm Venereol; 2018 Feb; 98(2):200-205. PubMed ID: 29110022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling Heterogeneity in Patients' Preferences for Psoriasis Treatments in a Multicountry Study: A Comparison Between Random-Parameters Logit and Latent Class Approaches.
    Boeri M; Saure D; Schacht A; Riedl E; Hauber B
    Pharmacoeconomics; 2020 Jun; 38(6):593-606. PubMed ID: 32128726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
    Bae SH; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC
    J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient benefit index (PBI) in the treatment of psoriasis--results of the National Care Study "PsoHealth".
    Radtke MA; Schäfer I; Blome C; Augustin M
    Eur J Dermatol; 2013 Apr; 23(2):212-7. PubMed ID: 23587940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A global approach to psoriatic patients through PASI score and Skindex-29.
    Prignano F; Ruffo G; Ricceri F; Pescitelli L; Lotti T
    G Ital Dermatol Venereol; 2011 Feb; 146(1):47-52. PubMed ID: 21317856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation Between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis Treated with Ustekinumab.
    Hesselvig JH; Egeberg A; Loft ND; Zachariae C; Kofoed K; Skov L
    Acta Derm Venereol; 2018 Mar; 98(3):335-339. PubMed ID: 29110019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial.
    Ellis CN; Mordin MM; Adler EY;
    Am J Clin Dermatol; 2003; 4(2):131-9. PubMed ID: 12553852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
    Petridis A; Panagakis P; Moustou E; Vergou T; Kallidis P; Mandekou-Lefaki I; Chaidemenos G; Sotiriadis D; Alexopoulou G; Haratsis Y; Antoniou C
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):768-775. PubMed ID: 29356149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Even well-controlled psoriasis patients have unmet treatment needs regardless of disease severity.
    Vaidya TS; Anderson KL; Feldman SR
    Dermatol Online J; 2015 Sep; 21(9):. PubMed ID: 26437293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis.
    Bergstrom KG; Arambula K; Kimball AB
    Cutis; 2003 Nov; 72(5):407-11. PubMed ID: 14655784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
    Ryan C; Kirby B; Collins P; Rogers S
    Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical meaningfulness of complete skin clearance in psoriasis.
    Strober B; Papp KA; Lebwohl M; Reich K; Paul C; Blauvelt A; Gordon KB; Milmont CE; Viswanathan HN; Li J; Pinto L; Harrison DJ; Kricorian G; Nirula A; Klekotka P
    J Am Acad Dermatol; 2016 Jul; 75(1):77-82.e7. PubMed ID: 27206759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.